George-Simeon 2048 x 1152
10 Feb

A small Seattle biotech wants to take on GlaxoSmithKline’s emerging Shingrix blockbuster. RA Capital is on board

curevovaccine News, Vaccines No Comments
GlaxoSmithKline’s Shingrix has quickly become one of the company’s best-selling products since first winning FDA approval in 2017. But a new biotech believes it can do better — and RA Capital is listening. Curevo Vaccine, a Seattle-based company, debuted a $60 million Series A on Thursday led by the prominent life sciences VC, aiming to fund a Phase IIb study…
Continue Reading
Curevo Presenting at World Vaccine Conference Congress (Washington) 816x633
28 Sep

Curevo Presenting at World Vaccine Conference Congress (Washington) Sept 28 – Oct 1

curevovaccine Events, Vaccines No Comments
Curevo Vaccine’s Steve Reed, PhD, Scientific Advisory and Executive Board member, and Lisa Shelton, ARNP, Associated Director Clinical Operations,  will be presenting at World Vaccine Congress Wednesday, September 30 @ 4:50pm EST/1:50pm PST , on Low side-effect safety profile demonstrated in phase 1 trial of shingles vaccine candidate CRV-101.  Join us to hear about the safety and a sneak peek into the…
Continue Reading
Shingles Vaccine by Curevo 4480 x 6720
18 Mar

SAHPRA Approval Press Announcement 2021

curevovaccine News, Press Releases, Vaccines No Comments
CUREVO VACCINE ANNOUNCES THE APPROVAL TO CONDUCT A PHASE 1B CLINICAL TRIAL IN SOUTH AFRICA TO EVALUATE SAFETY AND IMMUNOGENICITY OF ITS ADJUVANTED SUBUNIT INVESTIGATIONAL VACCINE, CRV-101, AGAINST VARICELLA (CHICKENPOX) IN HIV-POSITIVE CHILDREN. Curevo Vaccine, a clinical-stage biopharmaceutical company combining excellence in protein and adjuvant biology to develop new generation sub-unit vaccines of global importance, announced today that approval was…
Continue Reading
Shingle and Varicella vaccines at Curevo 6000x4000
15 Sep

Curevo Vaccine Announces Robust Antibody Response Results of Phase I Clinical Trial of Investigational Vaccine for Shingles CRV-101

curevovaccine News, Vaccines No Comments
SEATTLE–(BUSINESS WIRE)–Curevo Vaccine, a clinical stage biopharmaceutical company developing next generation vaccines for patients with infectious disease of global importance, today announced antibody response data from its completed Phase 1 study investigating the safety, tolerability, and immune system response of CRV-101 in several formulations. The administration of Curevo’s adjuvanted sub-unit Shingles investigational vaccine resulted in a robust antibody response against…
Continue Reading
Vaccines 1626 x 1080
26 Sep

Curevo Vaccine Announces Interim Results of Phase I Clinical Trial of CRV-101

curevovaccine News, Press Releases, Vaccines No Comments
SEATTLE–(BUSINESS WIRE)–Curevo, Inc., a Seattle-based biotechnology company invested in by GC Pharma, one of the largest therapeutic protein manufacturers in the world, has announced encouraging preliminary Phase I safety and tolerability results of their Shingles vaccine candidate, CRV-101. Interim trial results demonstrating a promising safety and tolerability profile of the vaccine in 90 healthy adults ≥18 to <50 were presented…
Continue Reading
GC Pharma to Establish Curevo 1080x1080
18 May

GC Pharma to Establish Curevo

curevovaccine News, Vaccines No Comments
GC Pharma to Establish Curevo – a Seattle-based New Company Dedicated to Development of New Vaccines GC Pharma, IDRI and MIBR Bringing Together to Develop Innovative Vaccines GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced the establishment of Curevo Inc. (“Curevo”). The newly established Seattle-based company’s goal is to support GC…
Continue Reading
1 2